Humoral Response and SARS-CoV-2 Infection Risk following the Third and Fourth Doses of the BNT162b2 Vaccine in Dialysis Patients

The optimal SARS-CoV-2 vaccination schedule in dialysis patients and the potential need for a fourth vaccine dose are debatable. We prospectively assessed the humoral responses to three and four doses of BNT162b2 among dialysis patients. The study included 106 dialysis patients; 60 (56.6%) and 46 (4...

Descripción completa

Detalles Bibliográficos
Autores principales: Einbinder, Yael, Perl, Jeffrey, Nacasch, Naomi, Bnaya, Alon, Shavit, Linda, Erez, Daniel, Shashar, Moshe, Halperin, Tamar, Grupper, Ayelet, Benchetrit, Sydney, Wand, Ori, Cohen-Hagai, Keren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Novel Research Findings
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501772/
https://www.ncbi.nlm.nih.gov/pubmed/35850101
http://dx.doi.org/10.1159/000525309
_version_ 1784795551463636992
author Einbinder, Yael
Perl, Jeffrey
Nacasch, Naomi
Bnaya, Alon
Shavit, Linda
Erez, Daniel
Shashar, Moshe
Halperin, Tamar
Grupper, Ayelet
Benchetrit, Sydney
Wand, Ori
Cohen-Hagai, Keren
author_facet Einbinder, Yael
Perl, Jeffrey
Nacasch, Naomi
Bnaya, Alon
Shavit, Linda
Erez, Daniel
Shashar, Moshe
Halperin, Tamar
Grupper, Ayelet
Benchetrit, Sydney
Wand, Ori
Cohen-Hagai, Keren
author_sort Einbinder, Yael
collection PubMed
description The optimal SARS-CoV-2 vaccination schedule in dialysis patients and the potential need for a fourth vaccine dose are debatable. We prospectively assessed the humoral responses to three and four doses of BNT162b2 among dialysis patients. The study included 106 dialysis patients; 60 (56.6%) and 46 (43.4%) received 3 and 4 vaccine doses, respectively. Anti-spike (anti-S) antibody titers significantly increased after the third vaccine dose, followed by a decline, yet still remained higher than all previous measurements. The fourth vaccine dose led to another profound rise in anti-S titers. The absolute increase following the fourth dose correlated with response to the third dose. Infection risk however was similar between patients vaccinated with three or four doses.
format Online
Article
Text
id pubmed-9501772
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-95017722022-09-24 Humoral Response and SARS-CoV-2 Infection Risk following the Third and Fourth Doses of the BNT162b2 Vaccine in Dialysis Patients Einbinder, Yael Perl, Jeffrey Nacasch, Naomi Bnaya, Alon Shavit, Linda Erez, Daniel Shashar, Moshe Halperin, Tamar Grupper, Ayelet Benchetrit, Sydney Wand, Ori Cohen-Hagai, Keren Am J Nephrol Novel Research Findings The optimal SARS-CoV-2 vaccination schedule in dialysis patients and the potential need for a fourth vaccine dose are debatable. We prospectively assessed the humoral responses to three and four doses of BNT162b2 among dialysis patients. The study included 106 dialysis patients; 60 (56.6%) and 46 (43.4%) received 3 and 4 vaccine doses, respectively. Anti-spike (anti-S) antibody titers significantly increased after the third vaccine dose, followed by a decline, yet still remained higher than all previous measurements. The fourth vaccine dose led to another profound rise in anti-S titers. The absolute increase following the fourth dose correlated with response to the third dose. Infection risk however was similar between patients vaccinated with three or four doses. S. Karger AG 2022-08 2022-07-18 /pmc/articles/PMC9501772/ /pubmed/35850101 http://dx.doi.org/10.1159/000525309 Text en Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
spellingShingle Novel Research Findings
Einbinder, Yael
Perl, Jeffrey
Nacasch, Naomi
Bnaya, Alon
Shavit, Linda
Erez, Daniel
Shashar, Moshe
Halperin, Tamar
Grupper, Ayelet
Benchetrit, Sydney
Wand, Ori
Cohen-Hagai, Keren
Humoral Response and SARS-CoV-2 Infection Risk following the Third and Fourth Doses of the BNT162b2 Vaccine in Dialysis Patients
title Humoral Response and SARS-CoV-2 Infection Risk following the Third and Fourth Doses of the BNT162b2 Vaccine in Dialysis Patients
title_full Humoral Response and SARS-CoV-2 Infection Risk following the Third and Fourth Doses of the BNT162b2 Vaccine in Dialysis Patients
title_fullStr Humoral Response and SARS-CoV-2 Infection Risk following the Third and Fourth Doses of the BNT162b2 Vaccine in Dialysis Patients
title_full_unstemmed Humoral Response and SARS-CoV-2 Infection Risk following the Third and Fourth Doses of the BNT162b2 Vaccine in Dialysis Patients
title_short Humoral Response and SARS-CoV-2 Infection Risk following the Third and Fourth Doses of the BNT162b2 Vaccine in Dialysis Patients
title_sort humoral response and sars-cov-2 infection risk following the third and fourth doses of the bnt162b2 vaccine in dialysis patients
topic Novel Research Findings
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501772/
https://www.ncbi.nlm.nih.gov/pubmed/35850101
http://dx.doi.org/10.1159/000525309
work_keys_str_mv AT einbinderyael humoralresponseandsarscov2infectionriskfollowingthethirdandfourthdosesofthebnt162b2vaccineindialysispatients
AT perljeffrey humoralresponseandsarscov2infectionriskfollowingthethirdandfourthdosesofthebnt162b2vaccineindialysispatients
AT nacaschnaomi humoralresponseandsarscov2infectionriskfollowingthethirdandfourthdosesofthebnt162b2vaccineindialysispatients
AT bnayaalon humoralresponseandsarscov2infectionriskfollowingthethirdandfourthdosesofthebnt162b2vaccineindialysispatients
AT shavitlinda humoralresponseandsarscov2infectionriskfollowingthethirdandfourthdosesofthebnt162b2vaccineindialysispatients
AT erezdaniel humoralresponseandsarscov2infectionriskfollowingthethirdandfourthdosesofthebnt162b2vaccineindialysispatients
AT shasharmoshe humoralresponseandsarscov2infectionriskfollowingthethirdandfourthdosesofthebnt162b2vaccineindialysispatients
AT halperintamar humoralresponseandsarscov2infectionriskfollowingthethirdandfourthdosesofthebnt162b2vaccineindialysispatients
AT grupperayelet humoralresponseandsarscov2infectionriskfollowingthethirdandfourthdosesofthebnt162b2vaccineindialysispatients
AT benchetritsydney humoralresponseandsarscov2infectionriskfollowingthethirdandfourthdosesofthebnt162b2vaccineindialysispatients
AT wandori humoralresponseandsarscov2infectionriskfollowingthethirdandfourthdosesofthebnt162b2vaccineindialysispatients
AT cohenhagaikeren humoralresponseandsarscov2infectionriskfollowingthethirdandfourthdosesofthebnt162b2vaccineindialysispatients

Ejemplares similares